The new coronavirus SARS-CoV-2 caused the 2019 coronavirus disease (COVID-19), which is now raging globally. In a new study, researchers from the Icahn School of Medicine in Mount Sinai outlined key information that gastroenterologists and patients with chronic digestive diseases need to know about SARS-CoV-2 / COVID-19. The relevant research results were published in the journal Clinical Gastroenterology and Hepatology, with the paper titled "What Should Gastroenterologists and Patients Know About COVID-19?".
Image from Clinical Gastroenterology and Hepatology, 2020, doi: 10.1016 / j.cgh.2020.03.020.
For patients with inflammatory bowel disease (IBD) who may be taking immunosuppressive drugs, coronavirus is particularly worrying. This paper provides clear guidance: Patients taking immunosuppressive drugs for inflammatory bowel disease should continue to take drugs. The risk of disease recurrence far exceeds the chance of contracting coronavirus. These patients should also follow the guidelines of the US Centers for Disease Control (CDC) for high-risk groups: avoid crowding and restrict travel.
Corresponding author of the paper, Dr. Ryan Ungaro of Icahn School of Medicine at Mount Sinai said, "This is a rapidly evolving field with new information emerging every day. Although COVID-19 is a major public health issue of global concern, it is important To understand its risks correctly, and to keep abreast of the latest research and recommendations, in order to provide our patients with the most accurate recommendations. "